LY4064809

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

PI3Kα H1047R mutation inhibitor

Related drugs:

‹

›

PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	LY4064809 Sensitive: D – Preclinical LY4064809 Sensitive : D	LY4064809 Sensitive: D – Preclinical LY4064809 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + LY4064809 Sensitive: D – Preclinical palbociclib + LY4064809 Sensitive : D	palbociclib + LY4064809 Sensitive: D – Preclinical palbociclib + LY4064809 Sensitive : D

Associations
(2)